US4141976A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for alleviating proliferative skin diseases
Assignee: University of Michigan (System)
•
Filing: 1977-06-21
•
Granted: 1979-02-27
•
Expires: 1997-06-21
Abstract
Abstract A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, substituted thioxanthines, alone or in combination with a glucocorticoid.
Inventors
- 👤 John J. Voorhees
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 16:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61K31/435; A61K31/44; A61K31/455; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/56; A61K31/57
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
107 words
A process for alleviating proliferative skin diseases which comprises administering to the afflicted human or animal a composition containing as its active component at least one of the compounds selected from the groups consisting of: 1. Xanthines of the formula ##STR22## wherein R and R 1 are selected from the group consisting of H, alkyl and hydroxyalkyl containing 1-7 carbon atoms, cycloalkyl containing 3-7 carbon atoms and aralkyl wherein the alkyl portion contains 1-7 carbon atoms, R 2 is selected from the group consisting of H, alkyl (1-4), and a complex with ethylenediamine, and Y is selected from the group consisting of H and thiol; and 2.
Claim 2
Dependent Claim
107 words
A process for alleviating proliferative skin diseases which comprises administering to the afflicted human or animal a composition containing as its active component at least one of the compounds selected from the groups consisting of: 1. Xanthines of the formula ##STR22## wherein R and R 1 are selected from the group consisting of H, alkyl and hydroxyalkyl containing 1-7 carbon atoms, cycloalkyl containing 3-7 carbon atoms and aralkyl wherein the alkyl portion contains 1-7 carbon atoms, R 2 is selected from the group consisting of H, alkyl (1-4), and a complex with ethylenediamine, and Y is selected from the group consisting of H and thiol; and 2.
Claim 3
Dependent Claim
108 words
Thioxanthines of the formula ##STR23## wherein R 1 is selected from the group consisting of methyl, ethyl, propyl and -CH 2 -CH═CH 2 ; R 2 is selected from the group consisting of methyl, ethyl, propyl, -CH 2 CH═CH 2 , isopropyl, isobutyl, CH 2 CCH 3 ═CH 2 , pentyl, 3-methoxy-propyl, 2-methyl-butyl, hexyl, benzyl, phenyl, phenethyl, and furfuryl; R 3 is selected from the group consisting of hydrogen, methyl and ethyl; said compounds being in association with a pharmaceutical carrier wherein said active component is present in an amount in the range of about 0.1 to about 15% w/v which is effective to alleviate a proliferative skin
Claim 4
Dependent Claim
108 words
Thioxanthines of the formula ##STR23## wherein R 1 is selected from the group consisting of methyl, ethyl, propyl and -CH 2 -CH═CH 2 ; R 2 is selected from the group consisting of methyl, ethyl, propyl, -CH 2 CH═CH 2 , isopropyl, isobutyl, CH 2 CCH 3 ═CH 2 , pentyl, 3-methoxy-propyl, 2-methyl-butyl, hexyl, benzyl, phenyl, phenethyl, and furfuryl; R 3 is selected from the group consisting of hydrogen, methyl and ethyl; said compounds being in association with a pharmaceutical carrier wherein said active component is present in an amount in the range of about 0.1 to about 15% w/v which is effective to alleviate a proliferative skin
Claim 5
Dependent Claim
24 words
disease. 2. A process in accordance with claim 1, wherein said active component is at least one of the compounds selected from Group 1.
Claim 6
Dependent Claim
20 words
A process in accordance with claim 1, wherein said active component is at least one compound selected from Group 2.
Claim 7
Dependent Claim
22 words
A process in accordance with claim 1, wherein said active component is administered in conjunction with a permissive dosage of a glucocorticoid.
References Cited (Backward Citations)
US2994640A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-02-26 | 1982-08-28 | 1983-02-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-02-26 | 1986-08-28 | 1987-02-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-02-26 | 1990-08-28 | 1991-02-27 | $7700.00 | Window Closed / Lapsed |